CGRP levels in autoimmune diseases: a systematic review and meta-analysis of its potential role as a biomarker.
文献摘要
Aim This systematic review and meta-analysis aimed to quantitatively evaluate calcitonin gene-related peptide (CGRP) concentrations across autoimmune diseases (psoriasis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis) and assess its clinical utility as a neuro-immune biofluid biomarker. Materials and methods PRISMA-compliant meta-analyses using random-effects models calculated standardized mean differences (SMDs, Hedges' g) from major databases, evaluating circulating biofluids (serum/plasma; 10 studies, 16 cohorts) both overall across all selected autoimmune diseases and stratified by individual disease entities, separately from localized compartments. Results Primary synthesis of circulating biofluids (533 cases, 363 controls) showed significant systemic CGRP elevation in autoimmune conditions (SMD = 0.63, 95% CI: 0.46-0.80, p 2 = 14.4%). Subgroup analyses confirmed elevated circulating CGRP in rheumatoid arthritis (SMD = 0.72), psoriasis (SMD = 0.73), and IBD (SMD = 0.57). Multiple sclerosis showed elevated serum CGRP during progressive phases (SMD = 1.06) versus unchanged CSF levels (SMD = 0.04). Trim-and-fill analysis confirmed estimate stability (adjusted SMD = 0.58). Conclusion Circulating CGRP is elevated across specific autoimmune pathologies, functioning as a dynamic indicator of active neuro-immune inflammation rather than a static universal marker. Clinical implementation requires prospective, longitudinal studies and standardized, isoform-specific quantification assays. Prospero registration number CRD420261458044.